A team of 44 researchers across multiple institutions has identified a potential game-changer in pain management: an opioid that relieves pain without triggering the biological machinery that makes opioids so dangerous. The compound, called DFNZ (N-desethyl-fluornitrazene), was derived from nitazenes, a class of synthetic opioids that had been abandoned in the 1950s due to their extreme potency. Now, after decades of being shelved, this class of drugs is getting a second look, and the results are surprising .

The opioid crisis has made finding safer pain medications a critical public health priority. Traditional opioids like morphine and fentanyl are essential for treating severe pain, but they come with a heavy cost: respiratory depression, tolerance, dependence, and addiction. For years, scientists believed that if you wanted powerful pain relief from an opioid, you had to accept all of these risks as an unavoidable package deal. DFNZ appears to challenge that assumption .

How Does DFNZ Work Differently From Other Opioids?

The story of DFNZ begins with an unexpected discovery. Researchers at the National Institutes of Health (NIH) started with a compound called FNZ, which they tagged with a radioactive marker so they could track it in the brain using PET imaging (positron emission tomography). What they found was remarkable: FNZ entered the brain for only about 5 to 10 minutes, yet pain relief lasted for at least two hours .

This disconnect between how long the drug stayed in the brain and how long the pain relief lasted led researchers to investigate further. They discovered that FNZ was being converted into DFNZ, a metabolite (a byproduct created when the body processes a drug) that stuck around much longer and did the actual work of relieving pain. In other words, the drug patients would receive isn't the drug that matters; it's what the body transforms it into .

DFNZ activates the mu-opioid receptor, the same target as morphine and fentanyl, but it does so in a way that appears to sidestep many of the dangers associated with traditional opioids. In laboratory studies using rodents, DFNZ produced effective pain relief without causing respiratory depression, tolerance, or significant withdrawal symptoms .

What Makes DFNZ Less Addictive Than Other Opioids?

Addiction to opioids is largely driven by dopamine, a neurotransmitter in the brain's reward circuitry. Most addictive drugs, including traditional opioids, trigger sharp, rapid bursts of dopamine that act as a teaching signal: this matters, do it again. DFNZ behaves differently. While it does increase dopamine, it does so slowly and gradually, creating a flatter, more sustained signal rather than sharp spikes .

To test this theory, researchers trained rodents to press a lever to receive doses of DFNZ. The animals did self-administer the drug, showing that it produces some rewarding effect. However, when the drug was replaced with saline (salt water), the animals stopped seeking it almost immediately. This is strikingly different from what happens with heroin, morphine, or fentanyl, where animals typically continue drug-seeking behavior even after the drug is removed .

"DFNZ has an unprecedented pharmacology for an opioid. It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety," said Michael Michaelides, senior author and NIDA investigator.

Michael Michaelides, Senior Author and NIDA Investigator, National Institute on Drug Abuse

Key Safety Findings From the Research

The research team conducted extensive testing in rodents to evaluate DFNZ's safety profile. The results challenged conventional wisdom about how powerful opioids behave:

• Respiratory Effects: At therapeutic doses, DFNZ produced a moderate and sustained increase in brain oxygen rather than depressing respiration, a major concern with traditional opioids.
• Tolerance and Dependence: Repeated doses of DFNZ did not result in tolerance (where the body adapts and requires higher doses), drug dependency, or meaningful withdrawal effects. Among 14 classic opioid withdrawal symptoms, researchers only observed irritability when handling DFNZ-treated animals.
• Dopamine Signaling: Unlike traditional opioids, DFNZ does not trigger the rapid dopamine bursts associated with strong drug-cue associations and cravings that drive relapse in addiction.

These findings are significant because they suggest that the prevailing assumption in pain medicine may be wrong. For decades, scientists believed that high-efficacy mu-opioid receptor drugs inevitably came with the full package of risks: pain relief, euphoria, respiratory depression, and addiction. DFNZ suggests this might not be the case .

What Happens Next? The Path to Human Trials

While the results in rodents are promising, it's important to emphasize that DFNZ has not yet been tested in humans. The research team plans to pursue additional preclinical studies to support an application for regulatory approval to conduct human trials. Several patient populations could potentially benefit from DFNZ, including those undergoing surgery, patients with cancer-related pain, and individuals with chronic pain who have a particularly high need for effective treatment .

Nora D. Volkow, director of the National Institute on Drug Abuse, emphasized the potential impact: "Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose. Developing a highly effective pain medication without these drawbacks would have enormous public health benefits" .

The research also has implications for treating opioid use disorder itself. Because DFNZ appears to have a lower addiction potential while still providing pain relief, it may be preferable to current opioid agonist medications used in addiction treatment, which carry their own risks of respiratory depression .

Why This Discovery Matters for the Addiction Crisis

The timing of this discovery is significant. Nitazenes, the class of drugs from which DFNZ was derived, began appearing in the illicit drug supply around 2020 and have been associated with overdose deaths. In response, the U.S. Drug Enforcement Administration placed several nitazene analogues into Schedule I, the most restrictive category .

However, the NIH researchers note that regulators did not panic and immediately ban all nitazenes when they first appeared. This restraint left room for scientific research, which led to the discovery of DFNZ's potential therapeutic benefits. This outcome illustrates an important principle: overly aggressive prohibition can sometimes prevent beneficial research. As one of the researchers noted, Schedule I restrictions buried psychedelic research for 50 years, and scientists are only now uncovering its therapeutic potential .

The discovery of DFNZ represents a rare case of what researchers call "evading the iron law of prohibition," which states that the harder enforcement becomes, the harder and more dangerous drugs become. Instead of simply creating a more potent and dangerous opioid, researchers may have found a safer one .

While DFNZ is still years away from potential human use, the research opens a new door in pain management. If these findings hold up in human trials, it could fundamentally change how we approach both pain treatment and opioid addiction, offering patients effective relief without the devastating risks that have defined the opioid crisis.